DeepMed Research

Rifapentine

Generic Name: Rifapentine

Brand Names: Priftin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₆₄N_₄O_₁₂

CAS Number: 61379-65-5

Unique Ingredient Identifier: XJM390A33U

Background: Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

Indication: For the treatment of pulmonary tuberculosis.

Associated Conditions: Active Tuberculosis, Late phase Tuberculosis

Clinical Trials

Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

Phase 2

Not yet recruiting

Conditions: Mild Spinal Tuberculosis

Interventions: Drug: Rifampin
Drug: Isoniazid
Drug: Rifapentine (RPT)
Drug: Pyrazinamide
Drug: Moxifloxacin
Drug: Ethambutol

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: Shandong University

Target Recruit Count: 300

Registration Number: NCT06917495

Locations: 🇨🇳
Shandong Public Health Clinical Center, Jinan, China

Latent Tuberculosis in Type 2 Diabetes

Phase 4

Active, not recruiting

Conditions: Latent Tuberculosis Infection

Interventions: Drug: Rifapentine and Isoniazid for 3 months
Drug: Isoniazid (INH) daily for 9 months

First Posted Date: 2025-03-13

Last Posted Date: 2025-03-13

Lead Sponsor: Taichung Veterans General Hospital

Target Recruit Count: 552

Registration Number: NCT06874725

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

Phase 1

Recruiting

Conditions: Pediatric HIV Infection
Latent Tuberculosis

Interventions: Drug: Rifapentine
Drug: Dolutegravir

First Posted Date: 2024-02-28

Last Posted Date: 2024-12-24

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 25

Registration Number: NCT06281834

Locations: 🇳🇬
University College Hospital, Ibadan, Oyo, Nigeria

Shortened Regimen for Drug-susceptible TB in Children

Phase 3

Recruiting

Conditions: Tuberculosis, Lymph Node
Mycobacterium Tuberculosis
Tuberculosis
Tuberculosis, Pulmonary

Interventions: Drug: Isoniazid
Drug: Pyrazinamide
Drug: Rifampin
Drug: Rifapentine
Drug: Moxifloxacin
Drug: Ethambutol

First Posted Date: 2024-02-12

Last Posted Date: 2025-05-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 860

Registration Number: NCT06253715

Locations: 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳
Dr. D.Y. Patil Medical College, Hospital and Research Center, Pune, India
🇮🇩
Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia

and more 4 locations

1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam

Phase 3

Not yet recruiting

Conditions: Tuberculosis Infection

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Rifapentine

First Posted Date: 2024-01-05

Last Posted Date: 2025-03-19

Lead Sponsor: Freundeskreis Für Internationale Tuberkulosehilfe e.V

Target Recruit Count: 350

Registration Number: NCT06191692

Locations: 🇻🇳
Ha Noi Lung Hospital, Hà Nội, Vietnam
🇻🇳
Vietnam National Lung Hospital, Hà Nội, Ha Noi, Vietnam

Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment

Phase 3

Not yet recruiting

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Sitafloxacin
Drug: Rifampin
Drug: Pyrazinamide
Drug: SMZ/TMP
Drug: Rifapentine
Drug: Ethambutol
Drug: Isoniazid
Drug: Moxifloxacin

First Posted Date: 2022-07-12

Last Posted Date: 2022-07-12

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 620

Registration Number: NCT05454345

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

Phase 1

Recruiting

Conditions: Pregnancy
Tuberculosis Infection
HIV Seropositivity

Interventions: Drug: Rifapentine
Drug: Isoniazid

First Posted Date: 2021-11-16

Last Posted Date: 2024-03-18

Lead Sponsor: The Aurum Institute NPC

Target Recruit Count: 252

Registration Number: NCT05122026

Locations: 🇿🇦
The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
🇿🇦
Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital, Klerksdorp, North-West, South Africa
🇿🇦
FAMily Centre for Research with Ubuntu (FAMCRU), Cape Town, South Africa

Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease

Phase 4

Not yet recruiting

Conditions: Latent Tuberculosis
Kidney Failure

Interventions: Drug: Rifampicin plus Isoniazid
Drug: Rifapentine plus Isoniazid
Drug: Rifampicin alone

First Posted Date: 2021-08-25

Last Posted Date: 2024-03-15

Lead Sponsor: Miguel Santín

Target Recruit Count: 225

Registration Number: NCT05021731

Ultra Curto (Ultra Short) TB Prevention Therapy

Phase 4

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifapentine 600 mg and INH 300 mg
Drug: Rifapentine 900 mg and INH 900 mg

First Posted Date: 2021-01-11

Last Posted Date: 2024-06-28

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 500

Registration Number: NCT04703075

Locations: 🇧🇷
Fundacao de Medicina Tropical Doutor Heitor, Manaus, AM, Brazil
🇧🇷
NAPDOT, Rio De Janeiro, RJ, Brazil

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

Phase 4

Withdrawn

Conditions: Tuberculosis
Hiv

Interventions: Drug: Rifapentine weekly
Drug: Rifapentine daily

First Posted Date: 2020-09-16

Last Posted Date: 2021-09-20

Lead Sponsor: Yale University

Registration Number: NCT04551573

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy